Bruin Biometrics appoints Jeff Greiner and Eve Kurtin to Board of Directors

http://photos.prnewswire.com/prnc/20131018/LA00429LOGO

– USA, CA – Bruin Biometrics, LLC (“BBI”) a medical device company developing innovative, point of care diagnostic devices, announced today the appointment of two new board members Jeff Greiner and Eve Kurtin, Pharm.D.

Jeff Greiner has previously served as the Chief Executive Officer, President, and Chief Operating Officer of Advanced Bionics, a medical device company that developed spinal cord stimulators and cochlear implants. The company was sold in three different transactions for over $3 billion dollars and is now owned by Boston Scientific (its neuromodulation division) and Sonova (its medical or cochlear implant division).

Eve Kurtin, in addition to being a BBI Board member, is Managing Director of Pacific Venture Group and Senior Advisor of VantagePoint Capital Partners. Eve has over 20 years’ experience as an operating executive and investor in healthcare. As founder and CEO of Physician Venture Management, a joint venture of UniHealth and Columbia/HCA, Eve oversaw the development and operation of physician networks nationwide. In addition, Eve has acted as a senior consultant to several major healthcare corporations, including UniHealth, where she oversaw a variety of new product development activities. Eve is also a founding member of the RAND Health Board of Advisors, an assembly of national leaders from both the public and private sectors working to improve the nation’s healthcare system.

“Both Jeff and Eve have deep expertise in the medical services and tech sectors. We are delighted to have them join the BBI team,” said Martin Burns, Chief Executive.

BBI is privately-held and based in Los Angeles, California.

 

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.